Download PDF
Semin Liver Dis 2009; 29(1): 074-090
DOI: 10.1055/s-0029-1192057
© Thieme Medical Publishers

Transplantation Pathology

Stefan G. Hübscher1
  • 1Department of Pathology, University of Birmingham, Birmingham, United Kingdom
Further Information

Publication History

Publication Date:
23 February 2009 (online)

    Permissions and Reprints

ABSTRACT

This article focuses on the main patterns of damage that are seen in liver allograft biopsies. As with the interpretation of liver biopsies from the native liver, clinicopathological correlation is very important. The therapeutic implications of the biopsy report should also be considered, in particular whether changes in immunosuppression are indicated. For some conditions, such as liver allograft rejection, histology remains the gold standard for diagnosis. In other cases, a likely cause of graft dysfunction may already have been identified by other methods, but liver biopsy still provides useful additional information (e.g., assessing disease severity in hepatitis C infection) and may identify an additional or alternative cause for graft dysfunction (e.g., coexistent metabolic fatty liver disease). In cases where there is a dual pathology, liver biopsy may also help to identify the predominant cause of graft damage.

KEYWORDS

Liver transplantation - rejection - recurrent disease - de novo disease - chronic hepatitis

REFERENCES

  • 1 Hübscher S G, Portmann B C. Transplantation pathology. In: Burt AD, Portmann BC, Ferrell LD MacSween's Pathology of the Liver. 5th ed. Edinburgh; Churchill Livingstone 2007: 815-879
    Google Scholar
  • 2 Olthoff K M, Reddy K R. First, do no harm: the question of liver biopsy in living liver donors.  Liver Transpl. 2008;  14(4) 420-422
    CrossrefPubMedGoogle Scholar
  • 3 Lo I J, Lefkowitch J H, Feirt N et al.. Utility of liver allograft biopsy obtained at procurement.  Liver Transpl. 2008;  14(5) 639-646
    CrossrefPubMedGoogle Scholar
  • 4 Pungpapong S, Krishna M, Abraham S C, Keaveny A P, Dickson R C, Nakhleh R E. Clinicopathologic findings and outcomes of liver transplantation using grafts from donors with unrecognized and unusual diseases.  Liver Transpl. 2006;  12(2) 310-315
    CrossrefPubMedGoogle Scholar
  • 5 Tran T T, Changsri C, Shackleton C R et al.. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors.  J Gastroenterol Hepatol. 2006;  21(2) 381-383
    CrossrefPubMedGoogle Scholar
  • 6 Lee J Y, Kim K M, Lee S G et al.. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center.  J Hepatol. 2007;  47(2) 239-244
    CrossrefPubMedGoogle Scholar
  • 7 Savas N, Coskun M, Bilezikci B et al.. Value of an individual liver biopsy in the preoperative evaluation of apparently healthy potential liver donors.  Liver Transpl. 2008;  14(4) 541-546
    CrossrefPubMedGoogle Scholar
  • 8 Simpson M A, Verbesey J E, Khettry U et al.. Successful algorithm for selective liver biopsy in the right hepatic lobe live donor (RHLD).  Am J Transplant. 2008;  8(4) 832-838
    CrossrefPubMedGoogle Scholar
  • 9 Nocito A, El Badry A M, Clavien P A. When is steatosis too much for transplantation?.  J Hepatol. 2006;  45(4) 494-499
    CrossrefPubMedGoogle Scholar
  • 10 McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien P A. Use of severely steatotic grafts in liver transplantation: a matched case-control study.  Ann Surg. 2007;  246(6) 940-946
    CrossrefPubMedGoogle Scholar
  • 11 Angele M K, Rentsch M, Hartl W H et al.. Effect of graft steatosis on liver function and organ survival after liver transplantation.  Am J Surg. 2008;  195(2) 214-220
    CrossrefPubMedGoogle Scholar
  • 12 Kupiec-Weglinski J W, Busuttil R W. Ischemia and reperfusion injury in liver transplantation.  Transplant Proc. 2005;  37(4) 1653-1656
    CrossrefPubMedGoogle Scholar
  • 13 Silva M A, Mirza D F, Murphy N et al.. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation.  Transplantation. 2008;  85(5) 718-725
    CrossrefPubMedGoogle Scholar
  • 14 Neil D A, Hübscher S G. Are parenchymal changes in early post-transplant biopsies related to preservation-reperfusion injury or rejection?.  Transplantation. 2001;  71(11) 1566-1572
    CrossrefPubMedGoogle Scholar
  • 15 Usuda M, Fujimori K, Koyamada N et al.. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation.  Transplantation. 2005;  79(1) 12-16
    CrossrefPubMedGoogle Scholar
  • 16 Haga H, Egawa H, Fujimoto Y et al.. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation.  Liver Transpl. 2006;  12(3) 457-464
    CrossrefPubMedGoogle Scholar
  • 17 Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan.  Hepatology. 2008;  47(1) 143-152
    CrossrefPubMedGoogle Scholar
  • 18 Demetris A J, Jaffe R, Tzakis A et al.. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers.  Am J Pathol. 1988;  132(3) 489-502
    PubMedGoogle Scholar
  • 19 Demetris A J, Murase N, Nakamura K et al.. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection.  Semin Liver Dis. 1992;  12(1) 51-59
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Dankof A, Schmeding M, Morawietz L et al.. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection.  Virchows Arch. 2005;  447(1) 87-93
    CrossrefPubMedGoogle Scholar
  • 21 Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection.  Clin Transplant. 2005;  19(1) 110-114
    CrossrefPubMedGoogle Scholar
  • 22 Jain A, Mohanka R, Orloff M et al.. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies.  Clin Transplant. 2006;  20(5) 624-633
    CrossrefPubMedGoogle Scholar
  • 23 Lorho R, Turlin B, Aqodad N et al.. C4d: a marker for hepatic transplant rejection.  Transplant Proc. 2006;  38(7) 2333-2334
    CrossrefPubMedGoogle Scholar
  • 24 Troxell M L, Higgins J P, Kambham N. Evaluation of C4d staining in liver and small intestine allografts.  Arch Pathol Lab Med. 2006;  130(10) 1489-1496
    PubMedGoogle Scholar
  • 25 Schmeding M, Dankof A, Krenn V et al.. C4d in acute rejection after liver transplantation: a valuable tool in differential diagnosis to hepatitis C recurrence.  Am J Transplant. 2006;  6(3) 523-530
    CrossrefPubMedGoogle Scholar
  • 26 Sakashita H, Haga H, Ashihara E et al.. Significance of C4d staining in ABO-identical/compatible liver transplantation.  Mod Pathol. 2007;  20(6) 676-684
    CrossrefPubMedGoogle Scholar
  • 27 Bellamy C O, Herriot M M, Harrison D J, Bathgate A J. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status.  Histopathology. 2007;  50(6) 739-749
    CrossrefPubMedGoogle Scholar
  • 28 Bouron-Dal Soglio D, Rougemont A L, Herzog D, Soucy G, Alvarez F, Fournet J C. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases.  Hum Pathol. 2008;  39(7) 1103-1110
    CrossrefPubMedGoogle Scholar
  • 29 Neuman U P, Neuhaus P. C4d immunostaining in acute humoral rejection after ABO blood group-incompatible liver transplantation.  Liver Transpl. 2006;  12(3) 356-357
    CrossrefPubMedGoogle Scholar
  • 30 International Panel . Banff schema for grading liver allograft rejection: an international consensus document.  Hepatology. 1997;  25(3) 658-663
    CrossrefPubMedGoogle Scholar
  • 31 Terminology for hepatic allograft rejection. International Working Party.  Hepatology. 1995;  22(2) 648-654
    CrossrefPubMedGoogle Scholar
  • 32 El-Refaie A M, Burt A D. Mast cells and c-Kit expression in liver allograft rejection.  Histopathology. 2005;  47(4) 375-381
    CrossrefPubMedGoogle Scholar
  • 33 Arikan C, Nart D, Kilic M, Yuksekkaya H A, Aydogdu S. Association of mast cells and liver allograft rejection.  Pediatr Transplant. 2008;  12(3) 347-352
    CrossrefPubMedGoogle Scholar
  • 34 Bilezikci B, Demirhan B, Kocbiyik A, Arat Z, Haberal M. Relevant histopathologic findings that distinguish acute cellular rejection from cholangitis in hepatic allograft biopsy specimens.  Transplant Proc. 2008;  40(1) 248-250
    CrossrefPubMedGoogle Scholar
  • 35 Yeh M M, Larson A M, Tung B Y, Swanson P E, Upton M P. Endotheliitis in chronic viral hepatitis: a comparison with acute cellular rejection and non-alcoholic steatohepatitis.  Am J Surg Pathol. 2006;  30(6) 727-733
    CrossrefPubMedGoogle Scholar
  • 36 Demetris A J, Adeyi O, Bellamy C O et al.. Liver biopsy interpretation for causes of late liver allograft dysfunction.  Hepatology. 2006;  44(2) 489-501
    CrossrefPubMedGoogle Scholar
  • 37 Sundaram S S, Melin-Aldana H, Neighbors K, Alonso E M. Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients.  Liver Transpl. 2006;  12(1) 58-64
    CrossrefPubMedGoogle Scholar
  • 38 Krasinskas A, Demetris A J, Poterucha J J, Abraham S. The prevalence and natural history of untreated central perivenulitis in adult allograft livers.  Liver Transpl. 2008;  14(5) 625-632
    CrossrefPubMedGoogle Scholar
  • 39 Hübscher S G. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies.  Liver Transpl. 2008;  14(5) 596-600
    CrossrefPubMedGoogle Scholar
  • 40 Sebagh M, Rifai K, Feray C et al.. All liver recipients benefit from the protocol 10-year liver biopsies.  Hepatology. 2003;  37(6) 1293-1301
    CrossrefPubMedGoogle Scholar
  • 41 Demetris A, Adams D, Bellamy C et al.. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel.  Hepatology. 2000;  31(3) 792-799
    CrossrefPubMedGoogle Scholar
  • 42 Lunz III J G, Contrucci S, Ruppert K et al.. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.  Am J Pathol. 2001;  158(4) 1379-1390
    PubMedGoogle Scholar
  • 43 Nakazawa Y, Jonsson J R, Walker N I et al.. Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection.  Hepatology. 2000;  32(6) 1240-1247
    CrossrefPubMedGoogle Scholar
  • 44 van den Heuvel M C, de Jong K P, Boot M, Slooff M J, Poppema S, Gouw A S. Preservation of bile ductules mitigates bile duct loss.  Am J Transplant. 2006;  6(11) 2660-2671
    CrossrefPubMedGoogle Scholar
  • 45 Gouw A S, van den Heuvel M C, Boot M, Slooff M J, Poppema S, de Jong K P. Dynamics of the vascular profile of the finer branches of the biliary tree in normal and diseased human livers.  J Hepatol. 2006;  45(3) 393-400
    CrossrefPubMedGoogle Scholar
  • 46 van den Heuvel M C, Gouw A S, Boot M, Slooff M J, Poppema S, de Jong K P. The finest branches of the biliary tree might induce biliary vascularization necessary for biliary regeneration.  J Hepatol. 2006;  44(5) 947-955
    CrossrefPubMedGoogle Scholar
  • 47 Oguma S, Belle S, Starzl T E, Demetris A J. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors.  Hepatology. 1989;  9(2) 204-209
    CrossrefPubMedGoogle Scholar
  • 48 Matsumoto Y, McCaughan G W, Painter D M, Bishop G A. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection.  Transplantation. 1993;  56(1) 69-75
    PubMedGoogle Scholar
  • 49 Neil D A, Hübscher S G. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts.  Hepatology. 2002;  35(3) 639-651
    CrossrefPubMedGoogle Scholar
  • 50 Demetris A J, Ruppert K, Dvorchik I et al.. Real-time monitoring of acute liver-allograft rejection using the Banff schema.  Transplantation. 2002;  74(9) 1290-1296
    CrossrefPubMedGoogle Scholar
  • 51 Bartlett A S, Ramadas R, Furness S, Gane E, McCall J L. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review.  Liver Transpl. 2002;  8(12) 1147-1153
    CrossrefPubMedGoogle Scholar
  • 52 Horoldt B S, Burattin M, Gunson B K et al.. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation?.  Liver Transpl. 2006;  12(7) 1144-1151
    CrossrefPubMedGoogle Scholar
  • 53 Kusne S, Blair J E. Viral and fungal infections after liver transplantation–part II.  Liver Transpl. 2006;  12(1) 2-11
    CrossrefPubMedGoogle Scholar
  • 54 Ohashi M, Sugata K, Ihira M et al.. Human herpesvirus 6 infection in adult living related liver transplant recipients.  Liver Transpl. 2008;  14(1) 100-109
    CrossrefPubMedGoogle Scholar
  • 55 Seehofer D, Rayes N, Tullius S G et al.. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.  Liver Transpl. 2002;  8(12) 1138-1146
    CrossrefPubMedGoogle Scholar
  • 56 Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations.  Transpl Infect Dis. 2006;  8(1) 21-30
    CrossrefPubMedGoogle Scholar
  • 57 Limaye A P, Bakthavatsalam R, Kim H W et al.. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.  Transplantation. 2006;  81(12) 1645-1652
    CrossrefPubMedGoogle Scholar
  • 58 Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.  J Clin Virol. 2006;  35(4) 474-477
    CrossrefPubMedGoogle Scholar
  • 59 Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?.  J Hepatol. 2006;  44(1) 19-23
    CrossrefPubMedGoogle Scholar
  • 60 Koch D G, Christiansen L, Lazarchick J, Stuart R, Willner I R, Reuben A. Posttransplantation lymphoproliferative disorder—the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.  Liver Transpl. 2007;  13(6) 904-912
    CrossrefPubMedGoogle Scholar
  • 61 Eghtesad B, Kadry Z, Fung J. Technical considerations in liver transplantation: what a hepatologist needs to know (and every surgeon should practice).  Liver Transpl. 2005;  11(8) 861-871
    CrossrefPubMedGoogle Scholar
  • 62 Jain A, Costa G, Marsh W et al.. Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1000 consecutive patients.  Transpl Int. 2006;  19(1) 27-37
    CrossrefPubMedGoogle Scholar
  • 63 Broelsch C E, Frilling A, Testa G et al.. Early and late complications in the recipient of an adult living donor liver.  Liver Transpl. 2003;  9(10, Suppl 2) S50-S53
    CrossrefPubMedGoogle Scholar
  • 64 Silva M A, Jambulingam P S, Gunson B K et al.. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom.  Liver Transpl. 2006;  12(1) 146-151
    CrossrefPubMedGoogle Scholar
  • 65 Hübscher S G. Transplant pathology of the liver.  Curr Diagn Pathol. 1994;  1 59-69
    PubMedGoogle Scholar
  • 66 Demetris A J, Kelly D M, Eghtesad B et al.. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome.  Am J Surg Pathol. 2006;  30(8) 986-993
    CrossrefPubMedGoogle Scholar
  • 67 Cescon M, Grazi G L, Varotti G et al.. Venous outflow reconstructions with the piggyback technique in liver transplantation: a single-center experience of 431 cases.  Transpl Int. 2005;  18(3) 318-325
    CrossrefPubMedGoogle Scholar
  • 68 Sebagh M, Debette M, Samuel D et al.. “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection.  Hepatology. 1999;  30(5) 1144-1150
    CrossrefPubMedGoogle Scholar
  • 69 Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation.  Hepatology. 1994;  20(1 Pt 1) 88-94
    CrossrefPubMedGoogle Scholar
  • 70 Koneru B, Sterling M J, Bahramipour P F. Bile duct strictures after liver transplantation: a changing landscape of the Achilles' heel.  Liver Transpl. 2006;  12(5) 702-704
    CrossrefPubMedGoogle Scholar
  • 71 Verdonk R C, Buis C I, Porte R J et al.. Anastomotic biliary strictures after liver transplantation: causes and consequences.  Liver Transpl. 2006;  12(5) 726-735
    CrossrefPubMedGoogle Scholar
  • 72 Verdonk R C, Buis C I, van der Jagt E J et al.. Nonanastomotic biliary strictures after liver transplantation, part 2: Management, outcome, and risk factors for disease progression.  Liver Transpl. 2007;  13(5) 725-732
    CrossrefPubMedGoogle Scholar
  • 73 Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies.  Liver Transpl. 2008;  14(6) 759-769
    CrossrefPubMedGoogle Scholar
  • 74 Sebagh M, Farges O, Kalil A, Samuel D, Bismuth H, Reynes M. Sclerosing cholangitis following human orthotopic liver transplantation.  Am J Surg Pathol. 1995;  19(1) 81-90
    CrossrefPubMedGoogle Scholar
  • 75 Sebagh M, Yilmaz F, Karam V et al.. The histologic pattern of “biliary tract pathology” is accurate for the diagnosis of biliary complications.  Am J Surg Pathol. 2005;  29(3) 318-323
    CrossrefPubMedGoogle Scholar
  • 76 Krishna M, Keaveny A P, Genco P V et al.. Clinicopathological review of 18 cases of liver allografts lost due to bile duct necrosis.  Transplant Proc. 2005;  37(5) 2221-2223
    CrossrefPubMedGoogle Scholar
  • 77 Hübscher S G. Recurrent and de-novo disease in the liver allograft.  Curr Opin Organ Transplant. 2006;  11(3) 283-288
    PubMedGoogle Scholar
  • 78 Schreuder T C, Hübscher S G, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?.  Transpl Int. 2008;  , July 24 (Epub ahead of print)
    PubMedGoogle Scholar
  • 79 Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation.  J Viral Hepat. 2007;  14(suppl 1) 89-96
    PubMedGoogle Scholar
  • 80 Demetris A J, Eghtesad B, Marcos A et al.. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.  Am J Surg Pathol. 2004;  28(5) 658-669
    CrossrefPubMedGoogle Scholar
  • 81 Regev A, Molina E, Moura R et al.. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation.  Liver Transpl. 2004;  10(10) 1233-1239
    CrossrefPubMedGoogle Scholar
  • 82 Petrovic L M. Early recurrence of hepatitis C virus infection after liver transplantation.  Liver Transpl. 2006;  12(11, Suppl 2) S32-S37
    CrossrefPubMedGoogle Scholar
  • 83 Netto G J, Watkins D L, Williams J W et al.. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the “hepatitis C 3” multi-institutional trial experience.  Arch Pathol Lab Med. 2006;  130(8) 1157-1162
    PubMedGoogle Scholar
  • 84 Burton Jr J R, Rosen H R. Acute rejection in HCV-infected liver transplant recipients: the great conundrum.  Liver Transpl. 2006;  12(suppl 2) S38-S47
    CrossrefPubMedGoogle Scholar
  • 85 Grassi A, Quarneti C, Ravaioli M et al.. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C.  Liver Transpl. 2006;  12(11) 1673-1681
    CrossrefPubMedGoogle Scholar
  • 86 Errico-Grigioni A, Fiorentino M, Vasuri F et al.. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation.  Liver Transpl. 2008;  14(3) 313-320
    CrossrefPubMedGoogle Scholar
  • 87 Feray C, Samuel D, Gigou M et al.. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection.  Hepatology. 1995;  22(4 Pt 1) 1084-1089
    CrossrefPubMedGoogle Scholar
  • 88 Saab S, Kalmaz D, Gajjar N A et al.. Outcomes of acute rejection after interferon therapy in liver transplant recipients.  Liver Transpl. 2004;  10(7) 859-867
    CrossrefPubMedGoogle Scholar
  • 89 Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation.  Liver Transpl. 2004;  10(7) 868-871
    CrossrefPubMedGoogle Scholar
  • 90 Stravitz R T, Shiffman M L, Sanyal A J et al.. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.  Liver Transpl. 2004;  10(7) 850-858
    CrossrefPubMedGoogle Scholar
  • 91 Stanca C M, Fiel M I, Kontorinis N, Agarwal K, Emre S, Schiano T D. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.  Transplantation. 2007;  84(2) 180-186
    CrossrefPubMedGoogle Scholar
  • 92 Walter T, Dumortier J, Guillaud O et al.. Rejection under alpha interferon therapy in liver transplant recipients.  Am J Transplant. 2007;  7(1) 177-184
    CrossrefPubMedGoogle Scholar
  • 93 Cholongitas E, Samonakis D, Patch D et al.. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus.  Transplantation. 2006;  81(3) 488-490
    CrossrefPubMedGoogle Scholar
  • 94 Kontorinis N, Agarwal K, Elhajj N, Fiel M I, Schiano T D. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.  Liver Transpl. 2006;  12(5) 827-830
    CrossrefPubMedGoogle Scholar
  • 95 Berardi S, Lodato F, Gramenzi A et al.. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?.  Gut. 2007;  56(2) 237-242
    CrossrefPubMedGoogle Scholar
  • 96 Khettry U, Huang W Y, Simpson M A et al.. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.  Hum Pathol. 2007;  38(3) 443-452
    CrossrefPubMedGoogle Scholar
  • 97 Fiel M I, Agarwal K, Stanca C et al.. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.  Liver Transpl. 2008;  14(6) 861-871
    CrossrefPubMedGoogle Scholar
  • 98 Firpi R J, Abdelmalek M F, Soldevila-Pico C et al.. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.  Liver Transpl. 2004;  10(10) 1240-1247
    CrossrefPubMedGoogle Scholar
  • 99 Neumann U P, Berg T, Bahra M et al.. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.  J Hepatol. 2004;  41(5) 830-836
    CrossrefPubMedGoogle Scholar
  • 100 Samuel D, Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.  J Hepatol. 2007;  46(6) 988-991
    CrossrefPubMedGoogle Scholar
  • 101 Bahra M, Neumann U P, Jacob D et al.. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).  Transplantation. 2007;  83(3) 351-353
    CrossrefPubMedGoogle Scholar
  • 102 Tretheway D, Jain A, LaPoint R et al.. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score?.  Liver Transpl. 2008;  14(5) 695-700
    CrossrefPubMedGoogle Scholar
  • 103 Pungpapong S, Nunes D P, Krishna M et al.. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C.  Liver Transpl. 2008;  14(9) 1294-1302
    CrossrefPubMedGoogle Scholar
  • 104 Bolognesi M, Quaglio C, Bombonato G et al.. Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color Doppler.  Liver Transpl. 2008;  14(5) 616-624
    CrossrefPubMedGoogle Scholar
  • 105 Carrion J A, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.  Liver Transpl. 2006;  12(12) 1791-1798
    CrossrefPubMedGoogle Scholar
  • 106 Corradi F, Piscaglia F, Flori S et al.. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.  Dig Liver Dis. 2008;  , July 29 [Epub ahead of print]
    PubMedGoogle Scholar
  • 107 Harada N, Soejima Y, Taketomi A et al.. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation.  Transplantation. 2008;  85(1) 69-74
    CrossrefPubMedGoogle Scholar
  • 108 Rigamonti C, Donato M F, Fraquelli M et al.. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.  Gut. 2008;  57(6) 821-827
    CrossrefPubMedGoogle Scholar
  • 109 Bolkhir A, Brunt E M, Solomon H S, Hayashi P H. Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.  Liver Transpl. 2007;  13(2) 309-311
    CrossrefPubMedGoogle Scholar
  • 110 Dixon L R, Crawford J M. Early histologic changes in fibrosing cholestatic hepatitis C.  Liver Transpl. 2007;  13(2) 219-226
    CrossrefPubMedGoogle Scholar
  • 111 Alsatie M, Pandya P, Chalasani N P. Insulin resistance, hepatitis C, and liver transplantation.  Liver Transpl. 2008;  14(2) 136-137
    CrossrefPubMedGoogle Scholar
  • 112 Cotler S J, Kallwitz E, TenCate V et al.. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation.  Transplantation. 2007;  84(5) 587-591
    CrossrefPubMedGoogle Scholar
  • 113 Delgado-Borrego A, Liu Y S, Jordan S H et al.. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance.  Liver Transpl. 2008;  14(2) 193-201
    CrossrefPubMedGoogle Scholar
  • 114 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review.  Liver Transpl. 2006;  12(12) 1813-1824
    CrossrefPubMedGoogle Scholar
  • 115 Neuberger J, Gunson B, Hübscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.  Liver Transpl. 2004;  10(4) 488-491
    CrossrefPubMedGoogle Scholar
  • 116 Charatcharoenwitthaya P, Pimentel S, Talwalkar J A et al.. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.  Liver Transpl. 2007;  13(9) 1236-1245
    CrossrefPubMedGoogle Scholar
  • 117 Sebagh M, Farges O, Emile J F, Bismuth H, Reynes M. An unusual pattern of hepatitis C virus infection in a liver allograft.  Histopathology. 1995;  27(2) 190-192
    CrossrefPubMedGoogle Scholar
  • 118 Keaveny A P, Gordon F D, Khettry U. Post-liver transplantation de novo hepatitis with overlap features.  Pathol Int. 2005;  55(10) 660-664
    CrossrefPubMedGoogle Scholar
  • 119 Sebagh M, Farges O, Dubel L, Samuel D, Bismuth H, Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation.  Transplantation. 1998;  65(10) 1328-1333
    CrossrefPubMedGoogle Scholar
  • 120 Khettry U, Anand N, Faul P N et al.. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study.  Liver Transpl. 2003;  9(1) 87-96
    CrossrefPubMedGoogle Scholar
  • 121 Robertson H, Kirby J A, Yip W W, Jones D E, Burt A D. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis.  Hepatology. 2007;  45(4) 977-981
    CrossrefPubMedGoogle Scholar
  • 122 Brandsaeter B, Schrumpf E, Clausen O P, Abildgaard A, Hafsahl G, Bjøro K. Recurrent sclerosing cholangitis or ischemic bile duct lesions—a diagnostic challenge?.  Liver Transpl. 2004;  10(8) 1073-1074
    CrossrefPubMedGoogle Scholar
  • 123 Charatcharoenwitthaya P, Lindor K D. Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers?.  Liver Transpl. 2008;  14(2) 130-132
    CrossrefPubMedGoogle Scholar
  • 124 Abu-Elmagd K M, Balan V. Recurrent primary sclerosing cholangitis: from an academic illusion to a clinical reality.  Liver Transpl. 2005;  11(11) 1326-1328
    CrossrefPubMedGoogle Scholar
  • 125 Demetris A J. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection.  Liver Transpl. 2006;  12(11, Suppl 2) S68-S72
    CrossrefPubMedGoogle Scholar
  • 126 Wiesner R H, LaRusso N F, Ludwig J, Dickson E R. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis.  Gastroenterology. 1985;  88(1 Pt 1) 108-114
    PubMedGoogle Scholar
  • 127 Harrison R F, Davies M H, Neuberger J M, Hübscher S G. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?.  Hepatology. 1994;  20(2) 356-361
    CrossrefPubMedGoogle Scholar
  • 128 Graziadei I W, Wiesner R H, Batts K P et al.. Recurrence of primary sclerosing cholangitis following liver transplantation.  Hepatology. 1999;  29(4) 1050-1056
    CrossrefPubMedGoogle Scholar
  • 129 Rowe I A, Webb K, Gunson B K, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience.  Transpl Int. 2008;  21(5) 459-465
    CrossrefPubMedGoogle Scholar
  • 130 Manns M P, Bahr M J. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self.  Hepatology. 2000;  32(4 Pt 1) 868-870
    CrossrefPubMedGoogle Scholar
  • 131 Hübscher S G. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome.  Liver Transpl. 2001;  7(4) 285-291
    CrossrefPubMedGoogle Scholar
  • 132 Gonzalez-Koch A, Czaja A J, Carpenter H A et al.. Recurrent autoimmune hepatitis after orthotopic liver transplantation.  Liver Transpl. 2001;  7(4) 302-310
    CrossrefPubMedGoogle Scholar
  • 133 Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation.  Liver. 1997;  17(6) 311-315
    PubMedGoogle Scholar
  • 134 Ayata G, Gordon F D, Lewis W D et al.. Liver transplantation for autoimmune hepatitis: a long-term pathologic study.  Hepatology. 2000;  32(2) 185-192
    CrossrefPubMedGoogle Scholar
  • 135 Duclos-Vallee J C, Sebagh M, Rifai K et al.. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence.  Gut. 2003;  52(6) 893-897
    CrossrefPubMedGoogle Scholar
  • 136 Kerkar N, Hadzic N, Davies E T et al.. De-novo autoimmune hepatitis after liver transplantation.  Lancet. 1998;  351(9100) 409-413
    CrossrefPubMedGoogle Scholar
  • 137 Heneghan M A, Portmann B C, Norris S M et al.. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.  Hepatology. 2001;  34(3) 464-470
    CrossrefPubMedGoogle Scholar
  • 138 Salcedo M, Vaquero J, Banares R et al.. Response to steroids in de novo autoimmune hepatitis after liver transplantation.  Hepatology. 2002;  35(2) 349-356
    CrossrefPubMedGoogle Scholar
  • 139 D'Antiga L, Dhawan A, Portmann B et al.. Late cellular rejection in paediatric liver transplantation: aetiology and outcome.  Transplantation. 2002;  73(1) 80-84
    PubMedGoogle Scholar
  • 140 Miyagawa-Hayashino A, Haga H, Egawa H et al.. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation.  Transplantation. 2004;  78(1) 128-135
    PubMedGoogle Scholar
  • 141 Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation.  J Hepatol. 2004;  40(1) 3-7
    PubMedGoogle Scholar
  • 142 Aguilera I, Sousa J M, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation.  Liver Transpl. 2004;  10(9) 1166-1172
    CrossrefPubMedGoogle Scholar
  • 143 Aguilera I, Sousa J M, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation.  Transplant Proc. 2005;  37(9) 3968-3969
    CrossrefPubMedGoogle Scholar
  • 144 Riva S, Sonzogni A, Bravi M et al.. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience.  Liver Transpl. 2006;  12(4) 573-577
    CrossrefPubMedGoogle Scholar
  • 145 Avitzur Y, Ngan B Y, Lao M, Fecteau A, Ng V L. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation.  J Pediatr Gastroenterol Nutr. 2007;  45(2) 222-227
    CrossrefPubMedGoogle Scholar
  • 146 Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E et al.. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation.  Transplantation. 2007;  83(8) 1126-1129
    CrossrefPubMedGoogle Scholar
  • 147 Venick R S, McDiarmid S V, Farmer D G et al.. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis.  Am J Transplant. 2007;  7(4) 955-963
    CrossrefPubMedGoogle Scholar
  • 148 Lohse A W, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation.  Hepatol Res. 2007;  37(Suppl 3) S462
    PubMedGoogle Scholar
  • 149 Lohse A W, Obermayer-Straub P, Gerken G et al.. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease—possible association with a steroid-resistant transplant rejection episode.  J Hepatol. 1999;  31(1) 149-155
    CrossrefPubMedGoogle Scholar
  • 150 Duclos-Vallee J C, Johanet C, Bach J F, Yamamoto A M. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis.  J Hepatol. 2000;  33(1) 163-166
    CrossrefPubMedGoogle Scholar
  • 151 Richter A, Grabhorn E, Helmke K, Manns M P, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation.  Clin Transplant. 2007;  21(3) 427-432
    CrossrefPubMedGoogle Scholar
  • 152 Demetris A J, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis?.  Liver Transpl. 2008;  14(6) 750-755
    CrossrefPubMedGoogle Scholar
  • 153 Neuberger J. Chronic allograft dysfunction: Diagnosis and management. Is it always progressive?.  Liver Transpl. 2005;  11(11, Suppl 2) S63-S68
    CrossrefPubMedGoogle Scholar
  • 154 Mells G, Neuberger J. Protocol liver allograft biopsies.  Transplantation. 2008;  85(12) 1686-1692
    CrossrefPubMedGoogle Scholar
  • 155 Abraham S C, Poterucha J J, Rosen C B, Demetris A J, Krasinskas A M. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.  Am J Surg Pathol. 2008;  32(7) 965-973
    CrossrefPubMedGoogle Scholar
  • 156 Evans H M, Kelly D A, McKiernan P J, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation.  Hepatology. 2006;  43(5) 1109-1117
    CrossrefPubMedGoogle Scholar
  • 157 Seyam M, Neuberger J M, Gunson B K, Hübscher S G. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence.  Liver Transpl. 2007;  13(7) 966-974
    CrossrefPubMedGoogle Scholar
  • 158 Syn W K, Nightingale P, Gunson B, Hübscher S G, Neuberger J M. Natural history of unexplained chronic hepatitis after liver transplantation.  Liver Transpl. 2007;  13(7) 984-989
    CrossrefPubMedGoogle Scholar
  • 159 Haagsma E B, van den Berg A P, Porte R J et al.. Chronic hepatitis E virus infection in liver transplant recipients.  Liver Transpl. 2008;  14(4) 547-553
    CrossrefPubMedGoogle Scholar
  • 160 Kamar N, Selves J, Mansuy J M et al.. Hepatitis E virus and chronic hepatitis in organ-transplant recipients.  N Engl J Med. 2008;  358(8) 811-817
    CrossrefPubMedGoogle Scholar
  • 161 Shaikh O S, Demetris A J. Idiopathic posttransplantation hepatitis?.  Liver Transpl. 2007;  13(7) 943-946
    CrossrefPubMedGoogle Scholar
  • 162 Herzog D, Soglio D B, Fournet J C, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients.  Liver Transpl. 2008;  14(7) 946-955
    CrossrefPubMedGoogle Scholar
  • 163 Mohamed R, Hübscher S G, Mirza D F, Gunson B K, Mutimer D J. Posttransplantation chronic hepatitis in fulminant hepatic failure.  Hepatology. 1997;  25(4) 1003-1007
    CrossrefPubMedGoogle Scholar
  • 164 Pappo O, Ramos H, Starzl T E, Fung J J, Demetris A J. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.  Am J Surg Pathol. 1995;  19(2) 192-206
    PubMedGoogle Scholar
  • 165 Slapak G I, Saxena R, Portmann B et al.. Graft and systemic disease in long-term survivors of liver transplantation.  Hepatology. 1997;  25(1) 195-202
    CrossrefPubMedGoogle Scholar
  • 166 Devarbhavi H, Abraham S, Kamath P S. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation.  Liver Transpl. 2007;  13(11) 1552-1556
    CrossrefPubMedGoogle Scholar
  • 167 Krasinskas A. The significance of nodular regenerative hyperplasia in the transplanted liver.  Liver Transpl. 2007;  13(11) 1496-1497
    CrossrefPubMedGoogle Scholar

Stefan G HübscherM.D. 

Department of Pathology, University of Birmingham

Birmingham B15 2TT, United Kingdom

Email: s.g.hubscher@bham.ac.uk

      >